Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2557)
All Articles published online
|
Feb 28, 2008 (publication date) through Nov 9, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Lu HY, Zhuang LW, Yu YY, Si CW, Li J, Zhang JJ, Zeng Z, Chen XY, Han ZH, Chen Y. Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients. World J Gastroenterol 2008; 14(8): 1268-1273 [PMID: 18300356 DOI: 10.3748/wjg.14.1268] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i8/1268.htm |
| Number | Citing Articles |
| 1 |
Guang-Wen Cao. Clinical relevance and public health significance of hepatitis B virus genomic variations. World Journal of Gastroenterology 2009; 15(46): 5761-5769 doi: 10.3748/wjg.15.5761
|
| 2 |
H. Y. Lu, L. W. Zhuang, Y. Y. Yu, C. W. Si. Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg‐positive chronic hepatitis B patients. Journal of Viral Hepatitis 2010; 17(s1): 59 doi: 10.1111/j.1365-2893.2010.01272.x
|
| 3 |
Li Gao, Yue Hu, Xiaofeng Shi, Xin Li, Dazhi Zhang, Hong Ren. 48 weeks outcome after cessation of nucleos(t)ide analogue therapy in chronic hepatitis B patients. Annals of Hepatology 2020; 19(3): 329 doi: 10.1016/j.aohep.2019.10.006
|
| 4 |
Seong Hee Kang, Keunhee Kang, Yeon Jong Eun, Young Sun Lee, Tae Suk Kim, Yang Jae Yoo, Sang Jun Suh, Eileen L. Yoon, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Kwan Soo Byun. Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study. Journal of Medical Virology 2017; 89(5): 849 doi: 10.1002/jmv.24715
|
| 5 |
Yuan-wang Qiu, Li-hua Huang, Wen-long Yang, Zhen Wang, Bo Zhang, Yi-guang Li, Ting-ting Su, Hong-yan Zhou, Wei Xu, Xue-dong Wang, Ya-ping Dai, Jian-he Gan. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients. International Journal of Infectious Diseases 2016; 43: 43 doi: 10.1016/j.ijid.2015.10.019
|
| 6 |
Kevin T. Chaung, Nghiem B. Ha, Huy N. Trinh, Ruel T. Garcia, Huy A. Nguyen, Khanh K. Nguyen, Gabriel Garcia, Aijaz Ahmed, Emmet B. Keeffe, Mindie H. Nguyen. High Frequency of Recurrent Viremia After Hepatitis B e Antigen Seroconversion and Consolidation Therapy. Journal of Clinical Gastroenterology 2012; 46(10): 865 doi: 10.1097/MCG.0b013e31825ceed9
|
| 7 |
Hui Zhang, Jianchun Xian, Yang Li, Li Xiao, Lu Wang, Muhammad Zia-Ul-Haq. Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine 2022; 2022: 1 doi: 10.1155/2022/1889628
|
| 8 |
Satoru Hagiwara, Naoshi Nishida, Tomohiro Watanabe, Hiroshi Ida, Toshiharu Sakurai, Kazuomi Ueshima, Masahiro Takita, Yoriaki Komeda, Norihiro Nishijima, Yukio Osaki, Masatoshi Kudo. Sustained Antiviral Effects and Clearance of Hepatitis Surface Antigen after Combination Therapy with Entecavir and Pegylated Interferon in Chronic Hepatitis B. Antiviral Therapy 2018; 23(6): 513 doi: 10.3851/IMP3225
|